ClinicalTrials.gg
RecruitingNCT07092540BABY DUCHENNEUpdated Aug 19, 2026

The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy

An observational study in Duchenne Muscular Dystrophy (DMD), sponsored by University of Rochester. Recruiting at 4 sites in United States. Open to male participants aged 0 Days to 3 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by University of Rochester · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
105
Ages
0 Days to 3 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 233 studies in Muscular Dystrophy, Duchenne with a site in United States — 35 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Planned enrollment
22nd of 55
105 · median 75
Started
2026
with 8 others
Observational
55 of 233
16 open now
Primary completion
2029-08
later than 39 of 59 live
Registered
219th of 233
by date

Among the 233 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 22nd largest by planned enrollment of the 55 observational ones that give a count, is one of 9 that started in 2026, is one of 55 observational ones, reaches primary completion later than 39 of the 59 other live ones, and was the 219th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

35 of the 233 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 0 Days to 3 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

The aim of the BABY DUCHENNE study is to evaluate the natural history and characterize the early clinical outcomes in very young children (0-3 years) with Duchenne muscular dystrophy (DMD) identified by newborn screening programs.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • New born screening
04

Who can participate

Ages eligible
0 Days to 3 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males with genetically confirmed diagnosis of DMD (Duchenne Muscular Dystrophy)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male child between birth and 3.0 years of age at time of enrollment.
  • A confirmed and documented pathogenic or likely pathogenic variant in the DMD gene.
  • Ability of parent/guardian to understand and provide written (signing Parental Permission and Consent Form).
  • Willingness of parent/guardian to comply with the protocol Schedule of Activities, including all study site visits.

Exclusion criteria

Exclusion Criteria:

  • Female
  • Presence of any confirmed genetic disease, other than DMD, that could impact early development, which, in the opinion of the PI, may confound interpretation of developmental progress.
  • Presence of any significant medical condition (i.e., extreme prematurity, hypoxic ischemic encephalopathy) which, in the opinion of the PI, may confound interpretation of the clinical course of DMD.
  • Inability/unwillingness of parent/guardian to provide written permission (sign PPF) or to comply with the protocol Schedule of Activities.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
105 participants (estimated)
Patient registry
No

Groups and cohorts

  • Boys (0-3) of age diagnosed with DMD via new born screening
06

What researchers measure

Primary outcomes

  1. Mean Change in Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Gross Motor Standard Score

    The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4), Gross Motor domain measures age-appropriate motor abilities such as crawling, standing, and walking in children aged 1 to 42 months. The Gross Motor Standard Score is derived by converting raw scores to age-normed standard scores (mean = 100; standard deviation = 15). Higher scores indicate better gross motor development.

    Time frame: Baseline to 36 months

Secondary outcomes

  1. Mean Change in Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Cognitive Standard Score

    The Bayley-4 Cognitive domain measures early cognitive development, including attention, memory, and problem-solving abilities. Standard scores range from 40 to 160 (mean = 100; standard deviation = 15). Higher scores reflect better cognitive performance.

    Time frame: Baseline to 36 months

  2. Mean Change in Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Fine Motor Standard Score

    The Bayley-4 Fine Motor domain assesses hand and finger coordination tasks such as reaching and grasping. Standard scores range from 40 to 160 (mean = 100; standard deviation = 15). Higher scores indicate better fine motor development.

    Time frame: Baseline to 36 months

  3. Mean Change in Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Expressive Language Standard Score

    The Bayley-4 Expressive Language Standard Score is derived by converting raw scores to age-normed standard scores based on normative data for children ages 1 to 42 months. Standard scores range from 40 to 160, with a mean of 100 and a standard deviation of 15. Higher scores indicate more advanced expressive language abilities.

    Time frame: Baseline to 36 months

  4. Mean Change in Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4) Receptive Language Standard Score

    The Bayley-4 Receptive Language domain assesses a child's ability to understand spoken language. Scores range from 40 to 160 (mean = 100; SD = 15). Higher scores reflect better language comprehension.

    Time frame: Baseline to 36 months

  5. Mean Change in World Health Organization Motor Milestone (WHOMM) Checklist Score

    The WHO Motor Milestone (WHOMM) checklist records developmental attainment of 6 gross motor milestones, scored as achieved or not achieved. The score reflects the number of milestones achieved at each visit. Higher scores indicate greater motor milestone attainment for age.

    Time frame: Baseline to 36 months

  6. Percentage of Participants Receiving Early Intervention Services

    This outcome measures the proportion of participants who have initiated any early intervention service (e.g., physical, occupational, or speech therapy), based on caregiver report or medical record review.

    Time frame: Baseline to 36 months

  7. Age at Initiation of Early Intervention Services

    This outcome records the age (in months) at which participants first received early intervention services, based on caregiver report or documentation in the medical record.

    Time frame: Baseline to 36 months

  8. Percentage of Participants Initiating Duchenne Muscular Dystrophy-Targeted Pharmacologic Treatment

    This outcome measures the proportion of participants who began any DMD-targeted pharmacologic treatment (e.g., corticosteroids, exon-skipping therapies) during the study period, based on caregiver report or medical records.

    Time frame: Baseline to 36 months

  9. Age at Initiation of Duchenne Muscular Dystrophy-Targeted Pharmacologic Treatment

    This outcome records the age (in months) at which each participant initiated pharmacologic treatment for Duchenne Muscular Dystrophy, as reported by caregivers or documented in the medical record.

    Time frame: Baseline to 36 months

  10. Percentage of Participants With a Neurobehavioral Diagnosis

    This outcome reports the percentage of participants diagnosed with a neurobehavioral condition (e.g., autism spectrum disorder, ADHD) during the study, based on caregiver report or medical record review.

    Time frame: Baseline to 36 months

  11. Age at First Neurobehavioral Diagnosis

    This outcome records the age (in months) at which each participant received their first neurobehavioral diagnosis, as determined by caregiver report or medical record.

    Time frame: Baseline to 36 months

  12. Mean Change in Duchenne Muscular Dystrophy Caregiver Reported Health Index Short Form (DMD-HI-SF) Score

    The DMD Caregiver Reported Health Index Short Form (DMD-HI-SF) is a caregiver-reported questionnaire assessing burden related to the child's health. Total score is derived by summing item responses and converting to a standardized T-score. Higher scores indicate greater symptom burden.

    Time frame: Baseline to 36 months

  13. Baseline North Star Ambulatory Assessment (NSAA) Total Score at Age 3 Years

    The NSAA is a 17-item clinician-rated motor function scale validated for ambulant children with DMD. Each item is scored from 0 (unable) to 2 (normal), for a total score range of 0 to 34. A single NSAA total score will be recorded at the time of the participant's first assessment at age 3 years.

    Time frame: Baseline to 36 months

07

Study locations

2 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2029, 38 months after the start.

Of 52 non-industry observational studies under Muscular Dystrophy, Duchenne, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 120. This study's planned 38 months is close to that.

Counting every sponsor, half of 63 studies reached it within 40 months; a quarter within 12 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 30, 2025
StartActual
Jun 3, 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2029
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07092540
Collaborators
United States Department of Defense
Responsible party
Bo Hoon Lee (Assistant professor of neurology, University of Rochester) — Principal investigator
First posted
Jul 30, 2025
Start date
Jun 3, 2026
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Aug 19, 2026

Study contacts

Kimberly A Hart, MA
Contact
Kim_Hart@urmc.rochester.edu
585-275-3767

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion